Mi SciELO
Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Nutrición Hospitalaria
versión On-line ISSN 1699-5198versión impresa ISSN 0212-1611
Resumen
PROANO-FIERRO, María Esther; RODRIGUEZ-CANETE, Blanca Leticia; SANCHEZ-SOBRINO, Paula y REGO-IRAETA, Antonia. Hypophosphatemia associated with use of intravenous ferric carboxymaltose. Nutr. Hosp. [online]. 2023, vol.40, n.6, pp.1301-1304. Epub 04-Mar-2024. ISSN 1699-5198. https://dx.doi.org/10.20960/nh.04806.
Introduction:
ferric carboxymaltose (CF) is an intravenous preparation that helps the rapid correction of anemia with a lower risk of adverse reactions. However, an association has been found between the administration of CF and the development of hypophosphatemia.
Case report:
we present the clinical case of a 57-year-old patient with a history of iron de-ficiency anemia who, after receiving treatment with CF (Ferinjet®) chronically, develops a clinical of severe muscle weakness. Laboratory tests showed hypophosphatemia, normocalcemia, normal vitamin D level (after correction) and increased renal excretion of phosphorus. After study, the diagnosis of chronic hypophosphatemia secondary to the use of CF is reached.
Discussion:
CF can cause an increase in FGF-23 which acts at the renal level inducing phosphaturia, which can generate severe hypophosphatemia. This case demonstrates the importance of recognizing and treating this clinical entity in time.
Palabras clave : Hypophosphatemia; Ferric carboxymaltose; FGF-23; Phosphaturia.